Network pharmacology analysis and experimental validation of EGCG's therapeutic effects against acute lung injury in sepsis
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115175 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Xianwei Jin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China; Medical In…. Hauptthemen laut MEDLINE: Sepsis, Acute Lung Injury, Catechin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Themen: Sepsis
Abstract (Originalsprache)
BACKGROUND: Acute lung injury (ALI), a severe pulmonary condition associated with sepsis, involves deterioration of alveolar and capillary endothelial cells during initial stages. Current therapeutic interventions remain insufficient. OBJECTIVE: This study investigates the therapeutic epigallocatechin gallate (EGCG) on sepsis-induced ALI and its underlying molecular mechanisms. METHODS: The effects of EGCG on M1 macrophage polarization and its glycolytic activity in sepsis models were evaluated through both in vitro and in vivo experiments. The targets of EGCG were identified using network pharmacology and molecular docking techniques, which were subsequently validated through experimental studies. The CCK-8 assay was employed to determine the optimal concentration of EGCG for maintaining the highest viability of LPS-treated RAW264.7 macrophages and bone marrow-derived macrophages (BMDMs). The sepsis models utilized included LPS-treated cell models and murine models established via cecal ligation and puncture (CLP). These models were evaluated through various biological methodologies, including qPCR, ELISA, and Western blot analysis across multiple dimensions. RESULTS: EGCG effectively reduced the expression of HK2, PKM2, and iNOS, mitigating lung damage in CLP mice. Network pharmacology analysis identified the epidermal growth factor receptor (EGFR) as a primary target, associated with the HIF-1α pathway. Mechanistically, EGCG reduced p-EGFR/EGFR, suppressing the expression of HIF-1α, HK2, PKM2, and iNOS. CONCLUSIONS: EGCG reduces ALI caused by sepsis by inhibiting macrophage glycolysis through the EGFR/HIF-1α signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Critical Care Medicine, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China; Medical Innovation Center, the First Affiliated Hospital, Jiangxi Medical Colleg…
- Department of Anesthesiology, the Second Affiliated Hospital of Nanchang University, Nanchang 330000, China.
- Department of Critical Care Medicine, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China; Jiangxi Provincial Key Laboratory of Prevention and Treatment of Infectious Dise…
Zitieren
APA
Jin, X., Weng, Q., Qian, K., & Liu, F. (2025). Network pharmacology analysis and experimental validation of EGCG's therapeutic effects against acute lung injury in sepsis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115175
Vancouver
Jin X, Weng Q, Qian K, Liu F. Network pharmacology analysis and experimental validation of EGCG's therapeutic effects against acute lung injury in sepsis. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115175
BibTeX
@article{Jin2025,
author = {Jin, Xianwei and Weng, Qiaoling and Qian, Kejian and Liu, Fen},
title = {Network pharmacology analysis and experimental validation of EGCG's therapeutic effects against acute lung injury in sepsis},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115175}
}
EUVIMED